Symbiosis Hired Commercial Staff for Global Growth
The manufacturer has added three specialists to support expanded injectable medicine capacity in key markets.
Updated on Oct. 12, 2026 in People
Live Poll
Do you believe corporate expansion in pharmaceutical manufacturing signals a strengthening domestic healthcare economy?
Symbiosis Pharmaceutical Services has hired three new commercial team members to support its international expansion across Southern Europe, the Asia-Pacific region, and the Middle East. The appointments follow the completion of a £26 million facility expansion.
Why it matters
The company is scaling its international commercial operations to align with its increased capacity for aseptic manufacturing. This shift targets deeper penetration of clinical and commercial supply chains in foreign markets.
Symbiosis added 3 new commercial staff members following the completion of its £26 million expansion program. This investment was designed to enhance the company's aseptic manufacturing capacity.
The players
Symbiosis Pharmaceutical Services
A contract development and manufacturing organization that specializes in the production of injectable medicines.
Payal Roychoudhury
A new member of the business development team focused on the Asia-Pacific region.
Joaquín Pérez Fornieles
A new business development specialist tasked with covering Southern Europe.
Annie Shafran
The new Inside Sales Manager who previously served as a Key Account Manager at LGC.
The details
The new hires are tasked with building regional client relationships and managing the increased inquiry volume stemming from the company's upgraded infrastructure. Payal Roychoudhury, Joaquín Pérez Fornieles, and Annie Shafran have been assigned to facilitate growth in target geographic segments. These additions, combined with recent leadership hires Jay Chima and Jos Vergeest, aim to convert the firm's expanded clinical and commercial supply capacity into new global contracts.
Timeline
October 12, 2026: Symbiosis announced three new commercial team appointments.
Market Landscape
This move follows the broader industry trend of contract development and manufacturing organizations scaling both physical capacity and specialized sales teams. It aligns with recent institutional investment in aseptic manufacturing to meet global demand for injectable medicine supply.
Operators should monitor whether the company's recent capital investment and headcount expansion effectively increase market share in the APAC and Southern European regions. Watch for changes in lead times or service availability as these new sales roles begin processing client inquiries.
The takeaway
Commercial expansion is a critical phase for businesses that have recently completed major capital projects. Operators should ensure that their sales headcount growth is timed to anticipate, rather than trail, the full activation of new service capacity.
Further reading
For more on shifts in industry hiring and executive movement, visit People.
Source note: This article includes information reported by Pharmafile.
Live Poll
Do you believe corporate expansion in pharmaceutical manufacturing signals a strengthening domestic healthcare economy?
